Prevention of CMV disease after organ transplant

Cytomegalovirus (CMV) disease after organ transplant refers to symptomatic infection caused by this ubiquitous beta-herpesvirus in solid organ allograft recipients

Cytomegalovirus (CMV) disease after organ transplant refers to symptomatic infection caused by this ubiquitous beta-herpesvirus in solid organ allograft recipients

The condition occurs when pharmacologic immunosuppression impairs cell-mediated immunity, permitting uncontrolled viral replication from newly transmitted donor graft virus or reactivation of latent endogenous virus Prophylactic management specifically targets recipients at risk, particularly CMV-seronegative recipients receiving allografts from seropositive donors, to suppress viral replication, preserve graft viability, and prevent systemic disease

The condition occurs when pharmacologic immunosuppression impairs cell-mediated immunity, permitting uncontrolled viral replication from newly transmitted donor graft virus or reactivation of latent endogenous virus

The condition occurs when pharmacologic immunosuppression impairs cell-mediated immunity, permitting uncontrolled viral replication from newly transmitted donor graft virus or reactivation of latent endogenous virus Clinically, it manifests either as CMV syndrome—characterized by fever, malaise, leukopenia, and thrombocytopenia—or as invasive tissue disease causing hepatitis, pneumonitis, gastrointestinal ulceration, and graft dysfunction

Clinically, it manifests either as CMV syndrome—characterized by fever, malaise, leukopenia, and thrombocytopenia—or as invasive tissue disease causing hepatitis, pneumonitis, gastrointestinal ulceration, and graft dysfunction

Clinically, it manifests either as CMV syndrome—characterized by fever, malaise, leukopenia, and thrombocytopenia—or as invasive tissue disease causing hepatitis, pneumonitis, gastrointestinal ulceration, and graft dysfunction

Prophylactic management specifically targets recipients at risk, particularly CMV-seronegative recipients receiving allografts from seropositive donors, to suppress viral replication, preserve graft viability, and prevent systemic disease